Symposium:
088. New Antibiotics: What's in the Pipeline
Thursday, October 5, 2017: 2:00 PM-3:30 PM
Room: 20ABCD

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • familiarize infectious disease clinicians with the clinical, microbiological, and pharmacological data of new antibiotics that are likely to be approved for clinical use
  • provide evidence-based data to support development of new antibiotics against multidrug-resistant microorganisms
  • explain the mechanism of action and strategies to overcome resistance that will have clinical application if the short term

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Pharmacists, Researchers, Scientists

Tracks: Trainee, Pediatric ID, Investigative ID, Epidemiology and Infection Control, Adult ID


Moderators:  Cesar Arias, MD, PhD, FIDSA, University of Texas Medical School at Houston , John Mohr, PharmD, Medical Affairs Strategic Solutions, LLC , David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health and Robert A. Bonomo, MD, Case Western Reserve University School of Medicine

Presentations:
2:00 PM
857
Delafloxacin
Sue K. Cammarata, MD

2:09 PM
858
Fosfomycin for Injection
Evelyn J. Ellis-Grosse, PhD

2:18 PM
859
Cefiderocol
Roger Echols, MD, FIDSA

2:27 PM
860
Plazomicin
Ian Friedland, MD

2:45 PM
862
Lefamulin
Steven P. Gelone, PharmD

2:54 PM
863
Iclaprim
David Huang, MD, PhD, FIDSA, FACP

3:03 PM
864
Meropenem-vaborbactam
Michael Dudley, PharmD, FIDSA

3:12 PM
865
Imipenem-Relebactam
Amanda Paschke, MD, MSCE

3:21 PM
866
Eravacycline
Patrick Horn, MD, PhD

CME Credits: No CME credit is offered for this session.

Disclosures:

C. Arias, The Medecins Company: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Merck: Grant Investigator , Grant recipient

J. Mohr, None

D. R. Andes, Medicines: Consultant , Consulting fee
Zavante: Consultant and Grant Investigator , Consulting fee and Grant recipient
Paratek: Research Contractor , Research grant
Actelion: Grant Investigator , Grant recipient
Amplyx: Grant Investigator , Grant recipient
Geom: Grant Investigator , Grant recipient
Meiji: Grant Investigator , Grant recipient
Cidaria: Grant Investigator , Grant recipient
Theravance: Consultant and Grant Investigator , Consulting fee and Grant recipient
Astellas: Grant Investigator , Grant recipient

R. A. Bonomo, Entasis: Grant Investigator , Research grant
Allecra: Grant Investigator , Research grant
Wockhardt: Grant Investigator , Research grant
Merck: Grant Investigator , Research grant
Roche: Grant Investigator , Research grant
GSK: Grant Investigator , Research grant
Allergan: Grant Investigator , Research grant
Shionogi: Grant Investigator , Research grant

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.